Dr Rebecca Zirnbauer

Dr Rebecca Zirnbauer joined QCGC Research in 2025. She trained in general surgery at the Medical University of Vienna and is completing a PhD in immunology. Her research in Vienna focused on tumour immunology, DNA damage responses, and stress-related biomarkers in gastrointestinal cancers, with multiple peer-reviewed publications in high-impact journals. 

At QCGC Research, Rebecca is investigating the prognostic role of Ki-67 in the feMMe trial cohort using AI-powered image analysis. This project aims to better define the role of Ki-67 as a biomarker for treatment stratification and long-term outcomes in endometrial cancer, particularly for women undergoing fertility-sparing or conservative management. By combining clinical trial data with advanced digital pathology, her work contributes to QCGC’s mission of developing biomarker-driven approaches that improve personalised treatment and quality of life for women affected by gynaecological cancers.